The global non-steroidal anti-inflammatory drugs (NSAIDs) market attained a value of USD 22.87 Billion in 2025, driven by a shift from opioid analgesics use of NSAIDs and enhancing client’s knowledge of their side effects across the globe. The market is further expected to grow at a CAGR of 5.40% between 2026 and 2035 to reach a value of USD 38.70 Billion by 2035.
Base Year
Historical Period
Forecast Period
The market value is expected to grow with a preference for NSAIDs for mild to moderate pain treatment and avoid opioid dependence.
Rising incidence of arthritis, muscle pain, premenstrual menstrual cramps, and injuries like sprains are likely to augment the market demand for NSAIDs in the forecast period.
The market is witnessing more investments intended to improve access to NSAIDs. Such efforts are expected to boost the market value in coming years.
Compound Annual Growth Rate
5.4%
Value in USD Billion
2026-2035
*this image is indicative*
Non-steroidal anti-inflammatory drugs (NSAIDs) are often used to alleviate pain, inflammation, and fever. Chronic pain being a long-term problem, that worsens health and economic issues due to reduced productivity and higher health costs. NSAIDs work by reducing prostaglandins (compounds that involved in causing pain and inflammation). These drugs help manage pain from arthritis, muscle pain, headache, premenstrual menstrual cramps, and injuries like sprains and strains. They are available without over the counter as common pain relievers like ibuprofen (Advil, Motrin) and naproxen (Aleve), and by prescription. Most NSAIDs are taken orally, but some are available as creams and gels for direct application to the skin to relieve localized pain.
Increasing Utilization of NSAIDs to Treat Multiple Conditions
With strong research and development investments, the global market for NSAIDs is set to grow in the forecast period. This growth is impacted by rising incidence of diseases that cause pain and inflammation. Bone and joint-related issues like rheumatoid arthritis and osteoarthritis comprise a major share wherein NSAIDs are used. In addition, surge in surgical procedures in hospitals is leading increased adoption of NSAIDs. Pain disorders and the aging population prone to various diseases are also increasing the need for the drugs. Additionally, rising support for pain management from end-users, helped by government and healthcare policies, ensures market expansion.
Increased Preference Over Opioids to Boost the Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market Demand
Despite the widespread use of opioids for pain relief, there is a growing trend towards prescribing NSAIDs due to the harmful effects of opioids. This has led to a push for safer pain management options. The American Academy of Family Physicians advises over-the-counter drugs like ibuprofen and naproxen as the primary treatment for mild to moderate pain. Such recommendations are likely to further boost the NSAIDs market value in the forecast period.
The EMR’s report titled “Non-steroidal Anti-Inflammatory Drugs (NSAIDs) Market Report and Forecast 2026-2035" offers a detailed analysis of the market based on the following segments:
Market Breakup by Disease Indication
Market Breakup by Drugs
Market Breakup by Route of Administration
Market Breakup by Distribution Channels
Market Breakup by Region
Arthritis Stands as the Most Dominant Category for the Forecast Period
The market segmentation based on disease indications is divided into arthritis, migraine, ophthalmic diseases, and others. Arthritis, including osteoarthritis and rheumatoid arthritis, is estimated to lead the market share in the forecast period. With chronic pain and inflammation as a common symptom, NSAID prescriptions are commonly referred by medical professionals. Ibuprofen-based products are especially popular because they work well and are easy to get. The rising prevalence of arthritis, especially in an aging population, significantly influences the NSAIDs market. NSAIDs also treat headaches and eye disorders, further boosting market growth. Ongoing research aims to meet the diverse needs of patients and healthcare providers.
Ibuprofen is Leading the Market Share Based on Drug Types
The market segmentation by drugs encompasses various drugs, which include over-the-counter drugs (Aspirin, Ibuprofen, Naproxen, Naproxen, Celecoxib, Others) and prescription (Daypro, Indocin, Lodine, Naprosyn, Relafen, Vimovo, Voltaren). Ibuprofen, an OTC medication, leads the market, due to its effectiveness in treating pain and inflammation. Its various formulations cater to different patient needs. Despite this, ibuprofen is preferred over aspirin for its wider usage across different ages and therapies. Research, policy changes, and new competitors may impact the market by either reducing ibuprofen’s market share or providing opportunities for new competitors to emerge.
North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa are all included in the regional market analysis. North America holds a substantial market share for NSAIDs because of the large population and common health issues such as arthritis and chronic pain present in this region. Developed nations ensure the availability of these drugs in healthcare facilities. Proper advertising informs customers about these products. Regulatory agencies such as the Food and Drug Administration in the USA and Health Canada inspect and verify NSAIDs' safety and efficacy before and after market approval.
In Asia Pacific region, many large companies manufacture and distribute NSAIDs, with strong research efforts to ensure quality and safety. Asia Pacific, with its large population and increasing arthritis cases, is expected to witness rapid growth in the forecast period. Government policies on treatment pricing and coverage, along with economic development in Southeast Asia and South Asia greatly influence demand.
In March 2024, Endo International plc launched the first flu pill. It is called ibuprofen-famotidine 800 mg/26. They launched it through their subsidiaries Par Pharmaceutical, Inc. This new generic medication, DUEXIS®, treats rheumatoid arthritis and osteoarthritis. It also reduces the risk of ulcers in the stomach and upper intestine that come from ibuprofen. This innovation offers better treatment options for arthritis patients. It shows Endo International’s commitment to advancing drugs.
In May 2023, AbbVie got approval from the U. S. Food and Drug Administration (FDA) for RINVOQ (upadacitinib). It's a new treatment for adults with moderately to severely active Crohn’s disease. This approval is expected to greatly impact the treatment of Crohn’s disease. It will give patients a new treatment choice and improve their quality of life. It is also likely to boost AbbVie’s revenues.
In January 2023, Sun Pharma acquired three brands from Aksigen Hospital Care, namely Disperzyme, Disperzyme-CD, and Phlogam (Trypsin BP 48 mg, Bromelain 90 mg), and Rutoside Trihydrate 100 mg. This acquisition is strategic and aims to improve Sun Pharma’s anti-inflammatory medicine range. It will provide more treatment options for patients. Sun Pharma hopes to use these well-known brands and to expand its market in anti-inflammatory drugs.
The key features of the market report include patent analysis, and strategic initiatives such as partnerships, and collaborations analysis by the leading players. The major companies in the market are as follows:
It is a Germany-based company that offers various NSAIDs including Aspirin (Bayer®, St. Joseph®). Ibuprofen (Motrin®, Advil®). Naproxen sodium (Aleve®)
Established in 1996 and headquartered in Switzerland, the company is involved in the production of various medications, including NSAIDs. One notable NSAID produced by Novartis is Diclofenac.
The company was established in 1849 and has its base in New York. It deals with various NASID products like Celecoxib, and Ibuprofen.
Based in the U.S., this company was founded in 1957. The company produces various NSAIDs which include Naproxen, Diclofenac,
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other companies in the market include Assertio Holdings, Inc., Amgen Inc., Lion Corporation, Dr. Reddy’s Laboratories Ltd., GlaxoSmithKline plc, and Sanofi India Limited.
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Upto 15% Off
USD
$3299 $2969
$5499 $4949
$6999 $5949
$8199 $6969
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Disease Indication |
|
| Breakup by Drugs |
|
| Breakup by Route of Administration |
|
| Breakup by Distribution Channels |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share